丙型肝炎藥物市場按藥物類別、給藥途徑、分銷管道和地區分類

預計 2025 年全球丙型肝炎藥物市場規模為 98.6 億美元，到 2032 年將達到 132.4 億美元，2025 年至 2032 年的複合年成長率為 4.3%。

數字。 2025年C型肝炎藥物市場佔有率（按地區）

丙型肝炎是一種肝臟感染疾病，可導致嚴重的肝損傷。它是由C型肝炎病毒引起的。美國約有240萬人受到影響。然而，大多數丙型肝炎患者不會出現任何症狀，因為該病毒很少引起症狀。病毒透過感染者的血液和體液傳播。

丙型肝炎分期潛伏期。這是從初次接觸到發病之間的時間段。潛伏期14～80天，平均45天。急性C型肝炎：這是病毒進入人體後持續六個月的短期疾病。有些人隨後能夠自行擺脫病毒。慢性C型肝炎大多數C型肝炎患者（高達 85%）會發展為長期疾病階段（持續時間超過 6 個月）。這被稱為慢性丙型肝炎感染，可導致肝癌和肝硬化等嚴重的健康問題。肝硬化。這種疾病會引起炎症，隨著時間的推移，健康的肝細胞會被疤痕組織所取代。飲酒或感染愛滋病毒會更快導致肝硬化，但肝臟通常需要約20至30年的時間才會發展為肝硬化。

市場動態：

預計預測期內全球丙型肝炎盛行率的上升將推動市場成長。例如，根據美國國家生物技術資訊中心2021年9月18日發布的數據，印度丙型肝炎病毒的盛行率為0.5%，約有470萬至1,090萬人受到影響。

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
• 全球丙型肝炎疫情呈上升趨勢
• 加強政府努力
  • 限制因素
• 副作用增加
  • 機會
• 提高不同地區的產品供應量
• 影響分析
• 主要亮點
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景

第4章丙型肝炎藥物市場-冠狀病毒 (COVID-19) 大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 丙型肝炎藥物市場（依藥物類別分類），2020 年至 2032 年

• NS3/4A蛋白酶抑制劑
• NS5A抑制劑
• NS5B聚合酵素抑制劑
• 伴隨用藥
• 其他

6. 2020 年至 2032 年按給藥途徑分類的C型肝炎藥物市場

• 口服藥物
• 靜脈
• 其他

7. 丙型肝炎藥物市場（依分銷管道分類），2020 年至 2032 年

• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年C型肝炎藥物市場（依地區分類）

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東
• 非洲

第9章 競爭態勢

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

第 10 章 章節

• 調查方法
• 關於出版商

Global Hepatitis C Drugs Market is estimated to be valued at USD 9.86 Bn in 2025 and is expected to reach USD 13.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.

Figure. Hepatitis C Drugs Market Share (%), By Region 2025

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

• By Drug Class
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs
  • Others
• By Route of Administration
  • Oral Drugs
  • Intravenous
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Gilead Sciences
  • AbbVie
  • Merck & Co
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Hoffmann-La Roche AG
  • Boehringer Ingelheim
  • Achillion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Growing Prevalence of Hepatitis C Globally
• Increasing Government Initiatives
  • Restraints
• Increasing Adverse Effects
  • Opportunities
• Increasing Product Availability in Various Regions
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Hepatitis C Drugs Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• NS3/4A Protease Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5A Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5B Polymerase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Combination Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Hepatitis C Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Hepatitis C Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Hepatitis C Drugs Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021-2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Achillion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us